Risk of hypertension eliminated with 10 dollars savings per patient through genomics; © panthermedia.net/Kirsty Pargeter
Using genome-wide analysis, investigators at the University of Montreal have potentially eliminated a lifetime drug prescription that two children with a previously unknown type of adrenal insufficiency had been receiving for 14 years.
Over a lifespan, the adjustment in treatment represents an approximate saving of 10,000 dollars in drug and test costs per patient. Moreover, the less invasive treatment regime can potentially reduce the lifetime risk of hypertension in the patients. "This is a real case of personalized medicine made possible today through the use of novel techniques in genomics," stated Doctor Mark Samuels.
Fourteen years ago both children were diagnosed with adrenal insufficiency, a condition that occurs when the adrenal glands do not secrete enough hormones to control sugar and mineral levels in the blood. After having sequenced the part of the genome that codes for genes in one patient, the investigators identified mutations in POMC, the gene behind the disorder. They then showed that the disorder in the second patient was also caused by a similar mutation in the gene POMC. Identifying the causal gene allowed them to conclude that the only thing missing in the patients was the production of cortisol, the hormone that regulates blood sugar. They thus advised the patients to continue cortisol treatment, but that fludrocortisone treatment was unlikely to be necessary. So far, fludrocortisone has been stopped in one patient without any adverse effects, while the condition of the second patient is still being evaluated.
In addition to reducing the risks of hypertension induced by fludrocortisone and allowing the patients and their family to feel more confident about the origin of the disease, the investigators' discovery made it possible to reduce by as much as 10,000 dollars the health costs for patients with this type of adrenal insufficiency. Over a 70-year lifespan, this is what the fludrocortisone treatment and the blood tests required in the patients treated with it adds up to.
The physicians did not modify the treatment earlier in the children's lives due to lack of a clear molecular diagnosis hence an imperfect understanding of the disease. Not only could withholding one of the replacement hormones have potentially led to a fatal outcome, but also analyzing the whole genome that led to the diagnosis would have been unthinkable just a few years ago. "Due to the astronomical costs associated previously with analyzing the whole genome, certain genes had to be targeted that were potentially responsible for the disorder and only these genes were analyzed in spite of the risk of not finding the right gene," explains Samuels. Today, lower genome analysis costs make an analysis of the whole genome affordable.
This case of personalized medicine made possible through novel genomic techniques is just the tip of the iceberg. In the near future, investigators hope to succeed in refining the treatment of many patients using these techniques.
MEDICA.de; Source: University of Montreal